Nexalin Technology Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment & Supplies Beta (adjusted)2.99 Intrinsic Value $1.03median of 2 methodsbased on filings through 30 Jun 2026 Market Price $7.55Price as of 1 Oct 2026 Significantly overvaluedIntrinsic value is 86% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (-86%) Data confidence Sign in to view data confidence Market Cap $6.5M Enterprise Value $5.5M Shares Outstanding 829.4K diluted Next Earnings Date16 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Nexalin Technology is a clinical-stage medical technology company developing non-invasive Deep Intracranial Frequency Stimulation (DIFS) devices for mental health and cognitive disorders. While the company's next-generation HALO Clarity device holds significant potential in the massive, underserved insomnia and neuropsychiatric markets, Nexalin faces severe near-term financial constraints. With minimal current revenues, a persistent net loss, and an auditor's going concern warning, the company is highly dependent on dilutive equity financing to fund its clinical trials. Furthermore, its Nasdaq listing is under immediate pressure due to a sub-$1.00 share price. Investors should maintain a Hold stance until the company secures a longer cash runway and demonstrates clinical progress in its upcoming pivotal trials. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$2.00 Mean target$2.00 High · most bullish analyst$2.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The company fails to regain Nasdaq compliance and is delisted to the OTC markets, severely limiting its access to capital. Clinical trial enrollment is delayed, and the remaining cash reserves are depleted, forcing highly dilutive emergency financing or a restructuring of operations. Base CaseCentral scenario The company successfully initiates and completes its 160-participant pivotal insomnia trial for HALO Clarity in collaboration with Lindus Health. It manages to maintain its Nasdaq listing through a reverse stock split or temporary price recovery and continues to fund operations via its ATM equity program, albeit with ongoing shareholder dilution. Bull CaseUpside scenario Successful FDA De Novo clearance of HALO Clarity for moderate-to-severe insomnia, establishing a new product category and driving rapid commercial scale-up through the NeuroCare virtual clinic. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |